使用注射用索玛鲁肽治疗肥胖症患者的特征、态度和体验：OUTSTEP 1 研究的中期分析.pdf

1、Vallis M et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Characteristics,attitudes and experiences of individuals using injectable semaglutide for obesity management:An interim analysis of the OUTSTEP 1 studyMichael Vallis,Salah Abusnana,Jennifer L.Baker,An

2、dreea Ciudin,Leyla Hernandez Donoso,Sandra Elia,Dmitry Estulin,Bruno Halpern,Samantha Hocking,Hyuk-Sang Kwon,Susanne Reger-Tan,Ricardo Reynoso,Hanen Samouda,Arya M.Sharma,on behalf of the OUTSTEP Study GroupAssociao Brasileira para o Estudo da Obesidade e Sndrome Metablica(ABESO),So Paulo,Brazil,and

3、 Obesity Center,Hospital 9 de Julho,So Paulo,BrazilThis study was sponsored by Novo Nordisk A/S and is registered with ClinicalTrials.gov(NCT07154238).Medical writing support was provided by Isabella Goldsbrough Alves,PhD,of Apollo,OPEN Health Communications,and funded by Novo Nordisk A/S,in accorda

4、nce with Good Publication Practice(GPP)guidelines(ismpp.org/gpp-2022).Scan QR code or visit the web site below for the oral presentation slides:https:/ M et al.Presented at the 33rd European Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Vallis M et al.Presented at the 33rd European Congress

5、 on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Disclosures Bruno Halpern has received funding as a speaker or advisory board consultant from:AstraZeneca Boehringer Ingelheim Currax Pharmaceuticals Daiichi Sankyo Eli Lilly Novartis Novo NordiskVallis M et al.Presented at the 33rd European Congress on

6、 Obesity(ECO),1215 May 2026,Istanbul,Trkiye.IntroductionThe aim of the OUTSTEP 1 study was to capture comprehensive insights into the experience,expectations and satisfaction level of patients using injectable semaglutide in the real worldUnderstanding real-world patient needs,expectations and attit